UNTOLD Ovarian Cancer Unmet Needs Survey

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorMasonic Cancer Center, University of Minnesota

About this trial

The goal of this study is to comprehensively measure ongoing concerns and unmet needs of individuals living with ovarian cancer. To accomplish this, the UNderstanding The experience of Ovarian cancer - Life after Diagnosis (UNTOLD) study will be conducted using a mixed-methods approach. Ovarian cancer survivors will be enrolled to participate in UNTOLD to complete a one-time survey regarding their experiences. Up to 40 survivors will be subsequently identified to complete a follow-up interview. To ensure these sample sizes, along with a representative sample, a combined recruitment strategy will be employed using the California Cancer Registry (population-based) and recruitment through ovarian cancer advocacy groups.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ability to read and write in English

Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube)

Disqualifiers

None

Trial population

Ovarian cancer survivors will be enrolled to participate in UNTOLD to complete a one-time survey regarding their experiences.

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

2,000 Participants
are grouped into 1 trial group
Group A: Ovarian Cancer Survivors

Trial outcomes

Primary outcomes

1

Supportive Care Needs

Composite Supportive Care Needs Survey - Short Form (SCNS-SF34) score minimum: 34, maximum: 170; continuous score; presented as mean and standard deviation.

Time frame
Day 1

Secondary outcomes

1

Quality of Life - Average FACT general total score

FACT-General total score minimum 0, maximum 108; continuous score; presented as mean and standard deviation

Time frame
Day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Masonic Cancer Center, University of Minnesota

Lead sponsor

Centers for Disease Control and Prevention

Collaborator